Core Insights - CoDiagnostics (CODX) has received a patent from the Australian Patent Office for its Co-Dx PCR platform, marking a significant milestone for its point-of-care technology [1][8]. Company Developments - The patent strengthens CODX's long-term commercialization strategy by securing intellectual property in Australia, a region that could become a vital market in the future [2][10]. - The Co-Dx PCR platform is still under regulatory review and not yet available for sale, but the patent enhances CODX's position for future commercialization and partnership opportunities [11][4]. - The patent covers the PCR Pro instrument and proprietary test cups, which are designed for high-quality PCR testing in decentralized settings [9][8]. Market Performance - Following the patent announcement, CODX shares fell by 21.1% at the market close, with a total decline of 35.5% over the past six months, contrasting with a 6.2% growth in the industry and a 14.1% gain in the S&P 500 during the same period [3][6]. Industry Outlook - The global molecular diagnostics market is projected to grow from an estimated $18.85 billion in 2025 to $25.59 billion by 2033, with a compound annual growth rate (CAGR) of 4.06% from 2026 to 2033 [12]. - Key drivers for this growth include technological advancements, an aging population, and increasing demand for precise genetic testing solutions [12].

Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [4] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [4] Upcoming Event - James Martin, CFO and co-CEO of Cocrystal, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, at 12:00 pm Eastern time [1] - The presentation will include a question-and-answer session with the live virtual audience [1] Investor Engagement - A video webcast of the presentation will be available within 48 hours after the event and archived for 90 days on the company's website [2] - Mr. Martin will be available for virtual one-on-one meetings with registered, qualified investors throughout the conference [2]